If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Also on Tiktok now too:
https://www.tiktok.com/@biotechtv/video/7365101459177950510
From the Interview the very least Sclp should get Is the deserved exposure for the variety and successful Trials results they have achieved. IMO
I would prefer a substantial RNS on Tuesday…..
If the aim is to get as much coverage as possible, a good starting point would be for Scancell themselves to retweet.
Agreed but the twitter video is very short compared to the full BioTech TV channel.
Maybe both links is the answer.
Just IMO if you're going to watch/share the video it's better to click/share the twitter link as it ticks the social media/YouTube boxes in one go.
Hi Burble
Yes that’s the one. The first mention was months ago and I would suspect the necessary forms had already been sent in.
These things don’t happen overnight but there should have been enough time for an NHS decision to be close.
If my mind serves me correctly, didn’t LD say that they may look to go for renal cell carcinoma with doublet checkpoint therapy with modi-1?
RCC currently can have nivolumab (Opdivo) with ipilimumab (Yervoy) as front line treatment. So similar to SCIB1 in melanoma.
During the interview LD says that they hope to trial Modi1 with a duplex of CPI’s.
I cannot remember which cancer indication that is in. What we do know is that it will be an NHS approved double checkpoint and we are looking to start a new cohort in that indication as part of an expanded ModiFY Trial.
This has been hinted at before so we can add that to the anticipated news list.
Another possible news item is in the ModiFY Renal cohort. Currently the patients we can enroll Modi1 is approved as a third line treatment and due good results we have applied to move that up to a first line treatment. I would imagine that would lead to much faster recruitment in that Cohort.
Reiterating a point made by someone else on here RE lack of mention of antibodies in the interview, noticably hush hush?
"04/5/2024
11:09 You'll have noted that antibodies were glossed over.Worth remembering there are five possible deals under discussion. Maybe the first of them next week?
markingtime"
Chelsea, interviews and posters okay call it progress.
@marcusl2 - for some reason your comment is getting the "Show additional replies, including those that may contain offensive content". Might be worth reposting it with some changes.
I’ve sent the link to Sky……………you never know.
Judging by the number of views, it looks like Brad's videos have quite a following. Great publicity for Scancell
Here is the full video as posted by bazookajr .
https://www.biotechtv.com/post/scancell-may-3-2024
Two of those were Loafas and Dracula, both of whom have accidentally on purpose hit the “Like” symbol.
Now on twitter:
https://twitter.com/BiotechTVHQ/status/1786276690102046945
1700 views already.
Interesting he questions that Lindy was asked - they would have been pre-prepared, and careful to avoid any info not already in the public domain. Lindy must know how the scib1 non-reported patients are doing and she was even more smiley than usual.
This was basically a message to investors saying "don't stress, everything is fine".
Scancell never, ever stand still, there will be stuff going on they can't talk about.
Agreed Chester. I also think that the picture here often gets very clouded by constant reference to investments made 10+ years ago. Not suggesting at all that isn’t factually correct for some posters but it’s also a hard fact that it’s less than 4 years since Redmile liked what they saw and fully backed the company with the cash needed to accelerate progress in the clinic.
That is a really excellent interview and clearly shows that Scancell are progressing towards data that will drive those products to market.
We are looking at the last quarter 2024 for the large clinical data reports but there is a lot more going on other than what was discussed. Absolutely no mention or questions on the potential of a GlyMab or AvidiMab deal. Deliberate, I would guess so.
When will investors realise that tackling the very hardest, most mature and highly immuno-suppressed cancers is the greatest challenge for any new technology.
To get any results is amazing and added to that Scancell’s science does it with minimal toxicity.
It’s been a long journey but the necessary positive results are clearly within Lindy Durrant’s sight.
Burble,
Yes, unless things have changed Cytokeratin 8 is one of the targets for Modi2..
Indeed Bermuda. Next step is a main LSE listing or a listing in the USA.
We should know which by this time next year.
I didn’t see that cardboard wall wobble once.
Agree excellent video, LD seems confident especially around Modi-1, SCIB1 and i SCIB1+.
So data Q3/Q4 - based on body language, I would hazard a guess that it’ll be Q4 for those. Interesting that the GlymAbs seem to be being explored in the ADC space - will be interesting to see what companies are hot in that area.
berm, you may be better placed to answer this but was there a slip of the tongue when she said cytokeratin being one of the targets for Moditope? Or is that in modi-2?
Bazookajr,
Excellent, thanks for the link.
My thoughts exactly Bermuda, best performance I have seen from LD, very upbeat and reassuring.